TITLE

Painkiller abuse plan rejected

AUTHOR(S)
Collier, Roger
PUB. DATE
September 2010
SOURCE
CMAJ: Canadian Medical Association Journal;9/7/2010, Vol. 182 Issue 12, pE578
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that the painkiller abuse reduction plan proposed by the U.S. Food and Drug Administration (FDA) has been rejected by an advisory panel of pain experts and doctors due to its weak capacity to resolve the problem.
ACCESSION #
54111041

 

Related Articles

  • The US FDA Draft Guidance for Developing Abuse-Deterrent Opioid Analgesics: 2014 and Beyond. Sellers, Edward; Shram, Megan; Schoedel, Kerri // Pharmaceutical Medicine - New Zealand;Dec2014, Vol. 28 Issue 6, p317 

    Prescription medication abuse, particularly of opioids, remains a serious public health problem. Many socioeconomic and healthcare system factors have contributed to the resulting epidemic of prescription opioid abuse. As the scope of this epidemic became evident, efforts to make abuse-deterrent...

  • FDA Tightens Indications for Using Long-Acting and Extended-Release Opioids to Treat Chronic Pain. Kuehn, Bridget M. // JAMA: Journal of the American Medical Association;10/16/2013, Vol. 310 Issue 15, p1547 

    The article discusses the U.S. Food and Drug Administration's (FDA) tightening of the indications for long-acting and extended-release versions of prescription opioid drugs in order to help prevent abuse and overdoses. According to FDA Commissioner Margaret A. Hamburg, the inappropriate use of...

  • FDA Committee: More Restrictions Needed on Hydrocodone Combination Products. Kuehn, Bridget M. // JAMA: Journal of the American Medical Association;3/6/2013, Vol. 309 Issue 9, p862 

    The article informs that the U.S. Food and Drug Administration (FDA) advisory committee has recommended tightening regulations on medications containing hydrocodone combination products. It mentions that the recommendation came owing to growing concern about abuse of prescription painkillers. It...

  • Counterirritants--The numbing truth. Goldemberg, Robert L. // DCI;Jan1994, Vol. 154 Issue 1, p48 

    Focuses on the effects of capsaicin. Use of pepper sprays for protection; Therapeutic category of capsaicin; Indications for Zostrix; Mechanism of action; Studies on the topical anaesthetic use of capsaicin; Capsaicin's action on pain sensations; Counterirritants listed in the US Food and Drug...

  • FDA Considers Stronger Warnings On OTCs. Branch Jr., Al // Pharmaceutical Executive;Nov2002, Vol. 22 Issue 10, p26 

    Reports on a U.S. Food & Drug Administration recommendation that over-the-counter pain killers should have stiffer warnings in light of continued episodes of liver and other intestinal organ damage when taken in combination with other drugs. Safety and efficacy of acetaminophen; Concern about...

  • Pentazocine--A Nonaddicting Analgesic. Bellville, J. Weldon // Annals of Internal Medicine;Nov67, Vol. 67 Issue 5, p1114 

    Editorial. Comments on the approval by the U.S. Food and Drug Administration of nonaddicting analgesic pentazocine for clinical use. Background on the drug; Review of literature on nonaddicting analgesics; Recommendations for physicians.

  • Action plan in place to curtail opioid analgesic abuse in US.  // Reactions Weekly;5/7/2011, Issue 1350, p2 

    This article reports on the launch of a programme by the U.S. Food and Drug Administration (FDA) to reduce the risk associated with all extended-release and long-acting opioid analgesics.

  • Painkillers to carry warning labels. Lund, Amy E. // Journal of the American Dental Association (JADA);Dec98, Vol. 129 Issue 12, p1670 

    Reports on a ruling of the United States Food and Drug Administration that mandates painkillers to carry warning labels. Contents of the warning; Effects of combining chronic alcohol ingestion and over-the-counter analgesic use.

  • Propoxyphene and Overdose Risk.  // Critical Care Alert;Sep2009 Pharmacology, p2 

    The article reports on the warnings of the Food and Drug Administration (FDA) on the overdose risk of propxyphene-containing pain drugs including Darvon® and Darvocet®.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics